Cardiovascular disease in transplant recipients: current and future treatment strategies
Saxenda is the form approved for weight management while Victoza is approved for T2DM
In a clinical trial, participants taking Semaglutide lost 15 percent of their body weight , on average
GLP-1 coverage cuts: What shifting payer policies mean for prescribing, access, and utilization Feb 18th, 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (sold under brandnames Wegovy and Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed how physicians and patients approach treatment for type 2 diabetes and obesity
Patients who were randomized to glimepiride were initially treated with 2 mg daily for two weeks, increasing to 4 mg daily for another two weeks, and finally increasing to 8 mg daily
Retatrutide results go beyond just the number on the scale